Advertisement

MD Anderson: We cooperated fully with CMS and implemented changes into our clinical practice

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

After a 23 year-old patient at MD Anderson Cancer Center died from complications stemming from a platelet transfusion that was contaminated with gram negative coccobacilli, hospital officials are revising internal protocols to demonstrate compliance with federal regulations.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Advertisement
Advertisement
Matthew Bin Han Ong
Matthew Bin Han Ong
Advertisement
Advertisement

YOU MAY BE INTERESTED IN

In an effort to target the right patients, genetic screening is becoming more common in clinical trials. But incorporating it can be complex and add a significant burden for both patients and clinical trial sites. Genetic counseling can streamline that process and help drug and gene therapy developers expedite the recruitment of genetically-eligible participants for their trials and use genetic testing results to accelerate the speed and success of clinical trials.
Advertisement
Advertisement